About Global Blood Therapeutics (NASDAQ:GBT)
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio-24.6862745098039
Forward P/E Ratio-24.59
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$4.99 per share
Price / Book12.62
Return on Equity-40.04%
Return on Assets-37.24%
Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions
What is Global Blood Therapeutics' stock symbol?
Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."
How were Global Blood Therapeutics' earnings last quarter?
Global Blood Therapeutics Inc (NASDAQ:GBT) issued its earnings results on Thursday, November, 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.04. During the same period in the previous year, the company posted ($0.58) EPS. View Global Blood Therapeutics' Earnings History.
When will Global Blood Therapeutics make its next earnings announcement?
Where is Global Blood Therapeutics' stock going? Where will Global Blood Therapeutics' stock price be in 2018?
14 brokers have issued 1 year target prices for Global Blood Therapeutics' stock. Their forecasts range from $46.00 to $91.00. On average, they expect Global Blood Therapeutics' stock price to reach $67.93 in the next twelve months. View Analyst Ratings for Global Blood Therapeutics.
What are Wall Street analysts saying about Global Blood Therapeutics stock?
Here are some recent quotes from research analysts about Global Blood Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "At ASH, Global Blood announced multi-dose Phase 2a data with voxelotor (GBT440), in adolescent (ages 12-17) patients." (12/11/2017)
- 2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (12/6/2017)
- 3. Cowen Inc analysts commented, "GBT reported Q3 earnings last week and provided a brief summary of their progress." (11/9/2017)
- 4. Wedbush analysts commented, "Global Blood Therapeutics (GBT) is developing GBT440 to reduce the severity and frequency of crises and pain associated with sickle cell disease (SCD) and to improve blood oxygenation characteristics and quality of life for IPF. In 2017, we see release of Phase 2a GBT440 testing in IPF as the most material catalyst unless GBT is acquired. We calculate that the recent uptick following acquisition speculation is too low."We believe GBT440's emerging clinical profile suggests potential for disease modification and becoming the foundation treatment for SCD. To date the emerging clinical profile includes a convenient once daily oral dosing; being safe and well tolerated and recent longer-term dosing suggests durability of effect and in our view partially de-risks Phase 3. Investor concerns include lack of dose response, new PRO and competition." (3/20/2017)
- 5. JPMorgan Chase & Co. analysts commented, "This evening GBT released 4Q results via press release (no conference call, as usual). The update was largely review and in-line with recent commentary; see our takeaways from the J.P. Morgan Healthcare Conference here. More significant than tonight’s print was Reuter’s report last week (here) that Novo Nordisk may have interest in GBT, and a subsequent Reuter’s story (here) that quoted NVO’s CEO saying “In my view we should do smaller deals; low single-digit billions of dollars.” On this front, we do believe that GBT could be a strong strategic fit for companies currently involved in the non-oncology hematology space. More broadly, we continue to think GBT440 is a promising wholly owned asset targeting a large and underserved market with the potential for initial IPF data later this year and a key sickle cell update currently anticipated in 2018." (3/15/2017)
Who are some of Global Blood Therapeutics' key competitors?
Some companies that are related to Global Blood Therapeutics include PRA Health Sciences (PRAH), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), FibroGen (FGEN), Anacor Pharmaceuticals (ANAC), Syneos Health (SYNH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Shire Viropharma (VPHM), Portola Pharmaceuticals (PTLA), Immunomedics (IMMU), Foundation Medicine (FMI), Puma Biotechnology (PBYI), Ironwood Pharmaceuticals (IRWD), Spectrum Pharmaceuticals (SPPI), Esperion Therapeutics (ESPR) and Crispr Therapeutics (CRSP).
Who are Global Blood Therapeutics' key executives?
Global Blood Therapeutics' management team includes the folowing people:
- Ted W. Love M.D., President, Chief Executive Officer, Director (Age 58)
- Jeffrey S. Farrow, Chief Financial Officer (Age 55)
- Peter Radovich, Senior Vice President, Operations (Age 39)
- Hing L. Sham, Senior Vice President, Research (Age 64)
- Jung E. Choi, Chief Business and Strategy Officer (Age 47)
- Tricia Borga Suvari Esq., Chief Legal Officer (Age 56)
- Charles J. Homcy M.D., Director (Age 68)
- Wendy L. Yarno, Director (Age 63)
- Willie L. Brown Jr, Independent Director (Age 83)
- Scott W. Morrison, Independent Director (Age 59)
When did Global Blood Therapeutics IPO?
(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.
Who owns Global Blood Therapeutics stock?
Global Blood Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (10.63%), BlackRock Inc. (7.22%), Citadel Advisors LLC (1.56%), RTW Investments LP (1.31%), Millennium Management LLC (1.04%) and Sectoral Asset Management Inc (0.96%). Company insiders that own Global Blood Therapeutics stock include Charles J Homcy, Deval L Patrick, Jung Choi, Kevin P Starr, Perceptive Advisors Llc, Peter Radovich and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics.
Who sold Global Blood Therapeutics stock? Who is selling Global Blood Therapeutics stock?
Global Blood Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, BlackRock Inc., Artal Group S.A., Sectoral Asset Management Inc, Compagnie Lombard Odier SCmA, Fernwood Investment Management LLC, Guggenheim Capital LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Charles J Homcy, Deval L Patrick, Jung Choi, Peter Radovich and Robert I Tepper. View Insider Buying and Selling for Global Blood Therapeutics.
Who bought Global Blood Therapeutics stock? Who is buying Global Blood Therapeutics stock?
Global Blood Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, RTW Investments LP, Millennium Management LLC, Citadel Advisors LLC, Farallon Capital Management LLC, ING Groep NV, Monashee Investment Management LLC and Driehaus Capital Management LLC. View Insider Buying and Selling for Global Blood Therapeutics.
How do I buy Global Blood Therapeutics stock?
Shares of Global Blood Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Global Blood Therapeutics' stock price today?
One share of Global Blood Therapeutics stock can currently be purchased for approximately $62.95.
How big of a company is Global Blood Therapeutics?
Global Blood Therapeutics has a market capitalization of $2.90 billion. The company earns $-82,460,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Global Blood Therapeutics employs 95 workers across the globe.
How can I contact Global Blood Therapeutics?
Global Blood Therapeutics' mailing address is 400 E Jamie Ct Ste 101, SOUTH SAN FRANCISCO, CA 94080-6230, United States. The company can be reached via phone at +1-650-7417700 or via email at [email protected]
MarketBeat Community Rating for Global Blood Therapeutics (GBT)MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Global Blood Therapeutics (NASDAQ:GBT) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$67.93||$64.08||$56.73||$52.91|
|Price Target Upside: ||12.56% upside||15.56% upside||47.54% upside||80.56% upside|
Global Blood Therapeutics (NASDAQ:GBT) Consensus Price Target History
Global Blood Therapeutics (NASDAQ:GBT) Analyst Ratings History
(Data available from 2/19/2016 forward)
Global Blood Therapeutics (NASDAQ:GBT) Earnings History and Estimates Chart
Global Blood Therapeutics (NASDAQ GBT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Global Blood Therapeutics (NASDAQ:GBT) Earnings Estimates
2018 EPS Consensus Estimate: ($2.77)
2019 EPS Consensus Estimate: ($3.23)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Global Blood Therapeutics (NASDAQ:GBT)
No dividend announcements for this company have been tracked by MarketBeat.com
Global Blood Therapeutics (NASDAQ GBT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 87.81%
Global Blood Therapeutics (NASDAQ GBT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/1/2018||Peter Radovich||Insider||Sell||812||$57.30||$46,527.60||6,221|| |
|1/23/2018||Peter Radovich||Insider||Sell||30,000||$60.00||$1,800,000.00||33,581|| |
|1/17/2018||Jung Choi||Insider||Sell||3,000||$52.85||$158,550.00||137,255|| |
|1/10/2018||Peter Radovich||Insider||Sell||15,000||$50.00||$750,000.00||17,684|| |
|12/19/2017||Perceptive Advisors Llc||Major Shareholder||Buy||175,000||$38.00||$6,650,000.00|| |
|12/18/2017||Jung Choi||Insider||Sell||3,000||$36.55||$109,650.00||135,255|| |
|10/30/2017||Peter Radovich||VP||Sell||12,500||$35.00||$437,500.00||2,684|| |
|10/27/2017||Charles J Homcy||Director||Sell||70,000||$33.97||$2,377,900.00||83,328|| |
|10/17/2017||Jung Choi||Insider||Sell||3,000||$32.65||$97,950.00||138,455|| |
|9/29/2017||Jung Choi||Insider||Sell||3,000||$30.00||$90,000.00||140,055|| |
|8/31/2017||Jung Choi||Insider||Sell||3,000||$30.00||$90,000.00||141,655|| |
|7/25/2017||Deval L Patrick||Director||Sell||27,053||$29.69||$803,203.57||12,053|| |
|7/21/2017||Jung Choi||Insider||Sell||3,000||$30.00||$90,000.00||143,255|| |
|4/6/2017||Robert I Tepper||Major Shareholder||Sell||31,225||$33.23||$1,037,606.75||229,773|| |
|12/16/2016||Kevin P Starr||Major Shareholder||Sell||108,955||$16.00||$1,743,280.00||82,544|| |
|1/7/2016||John Schembri||insider||Buy||1,500||$21.57||$32,355.00||1,500|| |
|12/22/2015||Eleanor Ramos||insider||Buy||11,000||$20.93||$230,230.00||11,000|| |
Global Blood Therapeutics (NASDAQ GBT) News Headlines
|Global Blood Therapeutics Inc to Post FY2022 Earnings of ($0.65) Per Share, SunTrust Banks Forecasts (GBT)|
www.americanbankingnews.com - February 19 at 9:18 AM
|Global Blood Therapeutics (GBT) Rating Increased to Strong-Buy at BidaskClub|
www.americanbankingnews.com - February 17 at 12:26 PM
|With an Eye on Biotech, Here's Today's Trading Thesis|
finance.yahoo.com - February 15 at 5:06 PM
|Global Blood Therapeutics (GBT) Research Coverage Started at Janney Montgomery Scott|
www.americanbankingnews.com - February 13 at 8:08 PM
|GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference - GlobeNewswire (press release)|
globenewswire.com - February 8 at 6:45 AM
|GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference|
finance.yahoo.com - February 8 at 6:45 AM
|The Confidence in the Dip Buyers Has Weakened|
finance.yahoo.com - February 8 at 6:45 AM
|Global Blood Therapeutics Inc (GBT) Given Average Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - February 6 at 5:26 PM
|Here's Why Global Blood Therapeutics Inc. Soared 47.1% in January|
www.fool.com - February 5 at 1:07 PM
|Global Blood Therapeutics Inc (GBT) Insider Sells $46,527.60 in Stock|
www.americanbankingnews.com - February 2 at 10:02 PM
|Insider Selling: Global Blood Therapeutics Inc (GBT) Insider Sells 30,000 Shares of Stock|
www.americanbankingnews.com - January 25 at 9:12 PM
|First Week of September 21st Options Trading For Global Blood Therapeutics (GBT) - Nasdaq|
www.nasdaq.com - January 25 at 3:27 PM
|Global Blood Therapeutics Inc Forecasted to Earn FY2017 Earnings of ($2.49) Per Share (GBT)|
www.americanbankingnews.com - January 25 at 7:50 AM
|William Blair Starts Global Blood Therapeutics (GBT) at Outperform; Says 30-50% Upside Remains, Including Potential ... - StreetInsider.com|
www.streetinsider.com - January 24 at 3:30 PM
|William Blair Values Global Blood Therapeutics' Stock At $80 - Benzinga|
www.benzinga.com - January 23 at 3:31 PM
|William Blair Values Global Blood Therapeutics' Stock At $80|
finance.yahoo.com - January 23 at 3:31 PM
|Global Blood Therapeutics Inc (GBT) Insider Sells $158,550.00 in Stock|
www.americanbankingnews.com - January 18 at 9:58 PM
|FY2017 Earnings Forecast for Global Blood Therapeutics Inc (GBT) Issued By Oppenheimer|
www.americanbankingnews.com - January 15 at 2:38 AM
|Global Blood Therapeutics Inc Expected to Earn FY2022 Earnings of $4.30 Per Share (GBT)|
www.americanbankingnews.com - January 13 at 3:12 PM
|Global Blood Therapeutics Inc (GBT) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - January 12 at 6:32 PM
|Peter Radovich Sells 15,000 Shares of Global Blood Therapeutics Inc (GBT) Stock|
www.americanbankingnews.com - January 12 at 12:36 AM
|Reviewing CytRx (CYTR) and Global Blood Therapeutics (GBT)|
www.americanbankingnews.com - January 11 at 8:14 AM
|Global Blood Therapeutics (GBT) Announces FDA Breakthrough Therapy Designation for Voxelotor for Treatment of SCD|
www.streetinsider.com - January 10 at 9:51 AM
|Why Global Blood Therapeutics Inc Is Rising Today|
www.fool.com - January 9 at 2:56 PM
|BRIEF-GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease|
www.reuters.com - January 9 at 9:43 AM
|GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference|
finance.yahoo.com - January 3 at 5:10 PM
|Head-To-Head Analysis: Global Blood Therapeutics (GBT) versus Spectrum Pharmaceuticals (SPPI)|
www.americanbankingnews.com - January 3 at 8:12 AM
|Global Blood Therapeutics: The Significance Of ASH Updates - Seeking Alpha|
seekingalpha.com - December 28 at 6:37 AM
|Global Blood Therapeutics (GBT) Downgraded by BidaskClub|
www.americanbankingnews.com - December 24 at 8:15 AM
|Upcoming Conversation With An Expert: What's The Potential Of Global Blood Therapeutics' Voxelotor (GBT440) In ... - Seeking Alpha|
seekingalpha.com - December 22 at 9:54 AM
|GBT Appoints Wendy L. Yarno to Board of Directors - GlobeNewswire (press release)|
globenewswire.com - December 22 at 9:54 AM
|GBT Appoints Wendy L. Yarno to Board of Directors|
finance.yahoo.com - December 22 at 9:54 AM
|Insider Selling: Global Blood Therapeutics Inc (GBT) Insider Sells 3,000 Shares of Stock|
www.americanbankingnews.com - December 20 at 6:04 PM
|Perceptive Advisors Llc Purchases 175,000 Shares of Global Blood Therapeutics Inc (GBT) Stock|
www.americanbankingnews.com - December 19 at 11:32 PM
|Global Blood Therapeutics Inc (GBT) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - December 18 at 8:30 PM
|Notable Mover Report On Dec 14, 2017 - Global Blood Therapeutics - Seeking Alpha|
seekingalpha.com - December 16 at 5:03 PM
|Global Blood Therapeutics (GBT) Stock Rating Reaffirmed by Wedbush|
www.americanbankingnews.com - December 15 at 8:38 PM
|5 Stocks To Watch For December 15, 2017 - Benzinga|
www.benzinga.com - December 15 at 10:12 AM
|Global Blood Therapeutics (GBT) Says it Priced $100M Common Stock Offering - StreetInsider.com|
www.streetinsider.com - December 15 at 10:12 AM
|Global Blood Therapeutics Prices a $100.0 Million Common Stock Public Offering|
finance.yahoo.com - December 15 at 10:12 AM
|Stock Traders Purchase High Volume of Put Options on Global Blood Therapeutics (GBT)|
www.americanbankingnews.com - December 15 at 3:38 AM
|FY2020 EPS Estimates for Global Blood Therapeutics Inc Boosted by Analyst (GBT)|
www.americanbankingnews.com - December 14 at 10:16 PM
|7 Stocks Moving In Thursday's After-Hours Session - Benzinga|
www.benzinga.com - December 14 at 5:40 PM
|Global Blood Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)|
globenewswire.com - December 14 at 5:40 PM
|Global Blood Therapeutics (GBT) Price Target Increased to $70.00 by Analysts at Needham & Company LLC|
www.americanbankingnews.com - December 14 at 10:22 AM
|Global Blood Therapeutics (GBT) Stock Rating Upgraded by BidaskClub|
www.americanbankingnews.com - December 12 at 10:48 PM
|Is Global Blood Therapeutics Inc’s (undefined:GBT) CEO Overpaid Relative To Its Peers?|
finance.yahoo.com - December 12 at 5:32 PM
|Global Blood Therapeutics And Crispr - Which Firm Will Capture The Lucrative Hemoglobinopathy Market? - Seeking Alpha|
seekingalpha.com - December 12 at 10:10 AM
|Oppenheimer Reiterates "$79.00" Price Target for Global Blood Therapeutics (GBT)|
www.americanbankingnews.com - December 12 at 10:04 AM
| Brokerages Anticipate Global Blood Therapeutics, Inc. (GBT) to Announce -$0.73 EPS|
www.americanbankingnews.com - December 12 at 9:26 AM
Global Blood Therapeutics (NASDAQ:GBT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Global Blood Therapeutics (NASDAQ:GBT) Income Statement, Balance Sheet and Cash Flow Statement
Global Blood Therapeutics (NASDAQ GBT) Stock Chart for Monday, February, 19, 2018